Given that targeting Myc still remains a major unrealized goal for cancer therapy, the direct inhibition of the Eya3–PP2A interaction by B55i may be a significantly less toxic means to target Myc in TNBC and other tumor types that overexpress Eya3. Here, EYA3 is linked to cancer.